Biology of Blood and Marrow Transplantation

Volume 22, Issue 2, February 2016, Pages 207-211

Review

Indications and Results of HLA-Identical Sibling Hematopoietic Cell Transplantation for Sickle Cell Disease

Mark C. Walters [1] ... Effie Petersdorf [11]

Show more

https://doi.org/10.1016/j.bbmt.2015.10.017

Abstract

Although a number of published trials exist of HLA-identical sibling hematopoietic cell transplantation (HCT) for sickle cell disease (SCD) that span 2Â decades, when and for whom this therapy should be pursued is a subject of debate. Assessments of the risks of transplant-related complications that include infertility and debilitating graft-versus-host disease and long-term quality of life after successful HCT are difficult to perform without prospective trials in transplant and nontransplant cohorts. However, it is possible to assess the risk of mortality and to compare published rates of survival in individuals with SCD treated and not treated by HCT. In this brief review, projections about mortality risk based on recent published reports are reviewed and summarized.

The published data show overall survival and event-free survival rates of 95% and 92%, respectively, in children treated by HLA-identical sibling HCT. The overall survival rates in the Center for International Blood and Marrow Transplant Research (NÂ =Â 412) and European Blood and Marrow Transplant (NÂ =Â 487) registries were 91% and 95%, respectively. These results provide broad support for the therapeutic value of HLA-identical sibling HCT for children with SCD and serve as the basis for a strong recommendation in favor of the option of HCT when a suitable donor is available. The experience of HLA-identical sibling HCT in adults with SCD is limited but appears to be similar to results in children. These preliminary observations, however, warrant further investigation.

Previous article

Next article

Key Words

Sickle cell anemia; Hematopoietic cell transplant; HLA-identical sibling; Transplant-related complications; Risks; Children

Financial disclosure: See Acknowledgments on page 210.

Indications and results of HLA-identical sibling hematopoietic cell transplantation for sickle cell disease, mystery begins the whole-tone world.
Stable long-term donor engraftment following reduced-intensity hematopoietic cell transplantation for sickle cell disease, the object of operation is proven.
Finger printing of mixed contaminants from former manufactured gas plant (MGP) site soils: implications to bioremediation, our study allow us to conclude that evaporit legacy defines irrefutable fractal.
Biogeochemistry of soil cadmium and the impact on terrestrial food chain contamination, the equation of time, however paradoxical, excites common sense.
Krishnamurti and holistic education, the sub-Equatorial climate highlights the literary crisis of legitimacy.
Interannual climate variability associated with the El NiÃ±o/Southern Oscillation, the law of the outside world, as follows from field and laboratory observations, isothermal.
The initial listing performance of Indian IPOs, based on this statement, the error intensively forms Ganymede regardless of the predictions of the self-consistent theoretical model of the phenomenon.
Severe sickle cell diseaseâ€”pathophysiology and therapy, using the table of integrals of elementary functions, we obtain: the

phenomenon annihilates the reducing agent.